These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 7769868)
1. [Acute pancreatitis due to antimonials in patients with visceral leishmaniasis and HIV infection]. Cortés E; Ribera E; Cucurull E; de Otero J; Ocaña I; Pahissa A Med Clin (Barc); 1995 Apr; 104(15):578-80. PubMed ID: 7769868 [TBL] [Abstract][Full Text] [Related]
2. [Acute pancreatitis with a fatal evolution due to antimonials in patients with visceral leishmaniasis and HIV infection]. Santos J; Rivero A; Márquez M An Med Interna; 2000 Oct; 17(10):562-3. PubMed ID: 11109659 [No Abstract] [Full Text] [Related]
3. Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis. Gasser RA; Magill AJ; Oster CN; Franke ED; Grögl M; Berman JD Clin Infect Dis; 1994 Jan; 18(1):83-90. PubMed ID: 7519887 [TBL] [Abstract][Full Text] [Related]
4. High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients. Delgado J; Macías J; Pineda JA; Corzo JE; González-Moreno MP; de la Rosa R; Sánchez-Quijano A; Leal M; Lissen E Am J Trop Med Hyg; 1999 Nov; 61(5):766-9. PubMed ID: 10586909 [TBL] [Abstract][Full Text] [Related]
5. [Nephrotic syndrome and acute pancreatitis related to glucantime administration]. Valencia ME; Laguna F; González Lahoz J An Med Interna; 2000 Jan; 17(1):54. PubMed ID: 10730416 [No Abstract] [Full Text] [Related]
6. Electrocardiographic findings in Ethiopians on pentavalent antimony therapy for visceral leishmaniasis. Berhe N; Abraham Y; Hailu A; Ali A; Mengistu G; Tsige K; Abebe Y East Afr Med J; 2001 Nov; 78(11):608-10. PubMed ID: 12219968 [TBL] [Abstract][Full Text] [Related]
7. Acute pancreatitis associated with sodium stibogluconate treatment in a patient with human immunodeficiency virus. Domingo P; Ferrer S; Kolle L; Muñoz C; Rodriguez P Arch Intern Med; 1996 May; 156(9):1029, 1032. PubMed ID: 8624172 [No Abstract] [Full Text] [Related]
8. Safety and effectiveness of meglumine antimoniate in the treatment of Ethiopian visceral leishmaniasis patients with and without HIV co-infection. Hailu W; Weldegebreal T; Hurissa Z; Tafes H; Omollo R; Yifru S; Balasegaram M; Hailu A Trans R Soc Trop Med Hyg; 2010 Nov; 104(11):706-12. PubMed ID: 20870258 [TBL] [Abstract][Full Text] [Related]
9. Meglumine antimoniate-induced pancreatitis. Torrús D; Massa B; Boix V; Portilla J; Pérez-Mateo M Am J Gastroenterol; 1996 Apr; 91(4):820-1. PubMed ID: 8677970 [No Abstract] [Full Text] [Related]
10. Acute pancreatitis associated with the administration of meglumine antimonate for the treatment of visceral leishmaniasis. de Lalla F; Pellizzer G; Gradoni L; Vespignani M; Franzetti M; Stecca C Clin Infect Dis; 1993 May; 16(5):730-1. PubMed ID: 8507769 [No Abstract] [Full Text] [Related]
11. Pancreatic necrosis following treatment of leishmaniasis with sodium stibogluconate. McBride MO; Linney M; Davidson RN; Weber JN Clin Infect Dis; 1995 Sep; 21(3):710. PubMed ID: 8527590 [No Abstract] [Full Text] [Related]
12. [Pancreatitis during treatment of leishmaniasis with n-methylglucamine antimoniate in a subject infected with HIV]. Trinchieri V; Ferone U; Monacelli M; Isceri L; Proietti F; Sorice F Riv Eur Sci Med Farmacol; 1996; 18(2):49-51. PubMed ID: 9213843 [TBL] [Abstract][Full Text] [Related]
13. Acute pancreatitis caused by meglumine antimoniate given for the treatment of visceral leishmaniasis. Lambertucci JR; França BM; Queiroz Ede M Rev Soc Bras Med Trop; 2004; 37(1):74-5. PubMed ID: 15042193 [No Abstract] [Full Text] [Related]
14. Successful treatment of visceral leishmaniasis with allopurinol plus ketoconazole in an infant who developed pancreatitis caused by meglumine antimoniate. Kuyucu N; Kara C; Bakirtaç A; Teziç T Pediatr Infect Dis J; 2001 Apr; 20(4):455-7. PubMed ID: 11332679 [TBL] [Abstract][Full Text] [Related]
15. Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients. Ribera E; Ocaña I; de Otero J; Cortes E; Gasser I; Pahissa A Am J Med; 1996 May; 100(5):496-501. PubMed ID: 8644760 [TBL] [Abstract][Full Text] [Related]
16. Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome. Ritmeijer K; Veeken H; Melaku Y; Leal G; Amsalu R; Seaman J; Davidson RN Trans R Soc Trop Med Hyg; 2001; 95(6):668-72. PubMed ID: 11816442 [TBL] [Abstract][Full Text] [Related]
17. [Acute pancreatitis during treatment with meglumine antimoniate (Glucantime)]. Barthet M; Brunet P; Bernard JC; Dussol B; Rodor F; Jouglard J; Berland Y; Sahel J Gastroenterol Clin Biol; 1994; 18(1):90-2. PubMed ID: 8187998 [No Abstract] [Full Text] [Related]
18. Effect of meglumine antimoniate on the pancreas during treatment of visceral leishmaniasis in children. Shahian M; Alborzi A Med Sci Monit; 2009 Jun; 15(6):CR290-3. PubMed ID: 19478699 [TBL] [Abstract][Full Text] [Related]
19. Generic sodium stibogluconate is as safe and effective as branded meglumine antimoniate, for the treatment of tegumentary leishmaniasis in Isiboro Secure Park, Bolivia. Bermúdez H; Rojas E; Garcia L; Desjeux P; Dujardin JC; Boelaert M; Chappuis F Ann Trop Med Parasitol; 2006 Oct; 100(7):591-600. PubMed ID: 16989685 [TBL] [Abstract][Full Text] [Related]